A phase 1 clinical trial has started for a divalent siRNA candidate targeting prion disease, marking the first human testing of the molecule described as a novel approach for the fatal neurodegenerative disorder. The study will evaluate safety, tolerability, and dosing. Prion diseases are rare but devastating, and drug development has historically struggled with both delivery and target biology. The move into first-in-human testing signals an effort to translate RNA interference strategies into a platform for disease modification. The trial design focus on determining dosing and tolerability early in development reflects typical phase 1 priorities, particularly for CNS-facing or difficult-to-deliver RNA therapeutics. Biotech investors and developers will monitor safety signals closely and look for whether target engagement translates into measurable pharmacodynamic effects as data emerge.